Tag: Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a median survival of 2-5 years from diagnosis [1.5.7]. This raises a critical question for patients and clinicians: **Does pirfenidone reverse fibrosis**, or does it only slow the decline?

Clinical trials, such as the open-label extension of the INPULSIS trials (INPULSIS-ON), have shown that the efficacy of nintedanib in slowing idiopathic pulmonary fibrosis (IPF) progression can be sustained over the long term, with some patients treated for up to 68 months. This evidence confirms that for chronic and progressive conditions, the answer to "how long should I take nintedanib?" is often for an extended period, potentially indefinitely.

Dopamine agonists like pramipexole play a key role in managing conditions such as Parkinson's disease, which affects millions worldwide. Understanding the difference between pramipexole and cabergoline is crucial for proper treatment, as these drugs, while both acting on dopamine receptors, vary significantly in their applications and side effect profiles.

Fibrotic diseases, characterized by organ scarring, represent a significant health burden, with idiopathic pulmonary fibrosis (IPF) being a primary example [1.2.2]. As of 2025, the key question, 'What is the new anti-fibrotic drug?', points towards nerandomilast, a promising agent nearing potential FDA approval [1.2.1, 1.2.5].

Transforming Growth Factor-beta (TGF-β), a powerful signaling protein, is involved in maintaining normal tissue health, but its dysregulated activity contributes significantly to diseases like fibrosis and cancer. Understanding **how to reduce TGF beta** is crucial for developing therapeutic strategies to combat these pathologies, moving beyond its physiological role to mitigate its harmful, disease-promoting effects.